Santhera Pharmaceuticals Holding Stock Working Capital
| SPHDF Stock | USD 9.42 0.00 0.00% |
Santhera Pharmaceuticals Holding fundamentals help investors to digest information that contributes to Santhera Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Santhera Pink Sheet. The fundamental analysis module provides a way to measure Santhera Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Santhera Pharmaceuticals pink sheet.
Santhera |
Santhera Pharmaceuticals Holding Company Working Capital Analysis
Santhera Pharmaceuticals' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Santhera Pharmaceuticals Working Capital | 64 M |
Most of Santhera Pharmaceuticals' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Santhera Pharmaceuticals Holding is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Based on the company's disclosures, Santhera Pharmaceuticals Holding has a Working Capital of 64 M. This is 84.96% lower than that of the Healthcare sector and 88.12% lower than that of the Biotechnology industry. The working capital for all United States stocks is 95.67% higher than that of the company.
Santhera Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Santhera Pharmaceuticals' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Santhera Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Santhera Pharmaceuticals by comparing valuation metrics of similar companies.Santhera Pharmaceuticals is currently under evaluation in working capital category among its peers.
Santhera Fundamentals
| Return On Equity | -13.16 | |||
| Return On Asset | -0.49 | |||
| Operating Margin | (386.18) % | |||
| Current Valuation | 60.45 M | |||
| Shares Outstanding | 61.81 M | |||
| Shares Owned By Insiders | 18.77 % | |||
| Shares Owned By Institutions | 3.50 % | |||
| Price To Earning | (6.80) X | |||
| Price To Book | 2.75 X | |||
| Price To Sales | 469.19 X | |||
| Revenue | (1.59 M) | |||
| Gross Profit | (5.36 M) | |||
| EBITDA | (34.57 M) | |||
| Net Income | (55.53 M) | |||
| Cash And Equivalents | 21.21 M | |||
| Cash Per Share | 0.43 X | |||
| Total Debt | 25.8 M | |||
| Current Ratio | 0.75 X | |||
| Book Value Per Share | (0.26) X | |||
| Cash Flow From Operations | (37.36 M) | |||
| Earnings Per Share | (1.68) X | |||
| Number Of Employees | 39 | |||
| Beta | 0.8 | |||
| Market Capitalization | 74.18 M | |||
| Total Asset | 91.12 M | |||
| Retained Earnings | (291 M) | |||
| Working Capital | 64 M | |||
| Current Asset | 74 M | |||
| Current Liabilities | 10 M | |||
| Z Score | -3.0 | |||
| Net Asset | 91.12 M |
About Santhera Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Santhera Pharmaceuticals Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Santhera Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Santhera Pharmaceuticals Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Other Information on Investing in Santhera Pink Sheet
Santhera Pharmaceuticals financial ratios help investors to determine whether Santhera Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Santhera with respect to the benefits of owning Santhera Pharmaceuticals security.